Compare Nucor Corporation (NUE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Sanofi SA — how do they compare? Nucor Corporation trades at $257.08 (market cap $58.17B), while Sanofi SA trades at $42.71 (market cap $104.06B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| NUE | SNY | |
|---|---|---|
Market Cap | $58.17B | $104.06B |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $52.34 |
52-Week Low | $131.78 | $41.33 |
Enterprise Value | $62.58B | $124.09B |
Dividend Yield | 0.87% | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor Corporation (NUE) trades at $256.40, down 1.79% on the day, with a bullish technical signal supported by moving averages and strong institutional interest. The company shows improving fundamentals with recent earnings beats (Q1 and Q2 2026) and projected revenue growth to $36.1B in 2026. Analyst consensus remains positive with a $277.57 price target, though recent trade tensions and cyclical steel industry challenges present headwinds.
NUE offers value with reasonable valuation multiples (P/E 20.46, P/S 1.63) and strong profitability metrics (ROE 13.52%). Key risks include exposure to steel price volatility and macroeconomic sensitivity, but infrastructure demand and tariff protections provide tailwinds. Institutional accumulation and dividend stability support the investment case for long-term investors.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
